Biotechnology company Celgene ( CELG) late Monday said that it would miss Street estimates for 2007 and that revenue rose 60% from a year ago.

The company forecasts 2007 sales of $1.3 billion and adjusted EPS of a dollar. Analysts at Thomson First Call are looking for 2007 revenue of $1.38 billion and adjusted earnings of $1.09.

Celgene said that 2006 revenue increased to $890 million on strong sales of Revlimid that ranged from $315 million to $320 million for 2006. Thalomid sales ranged from $425 million to $430 million. Adjusted earnings per share nearly tripled in 2006.

Earlier this week, the Summit, N.J.-based pharmaceutical company named its chief executive, Sol Barer, to an added chairman's post.

Shares of Celgene were recently off 3%, or $1.72, to $55.58 in after-hours trading.

Celgene will report its official 2006 financial results on Feb. 1.